Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julien Adam

Showing results (121-130 of 152) with videos related to

Pageof 16
Sort By:
JCO Precision Oncology|September 11, 2020
Real-World Utility of an Amplicon-Based Next-Generation Sequencing Liquid Biopsy for Broad Molecular Profiling in Patients With Advanced Non-Small-Cell Lung CancerJordi Remon, Ludovic Lacroix, Cecile Jovelet, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 30, 2018
Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiativeAurélie Auguste, Catherine Genestie, Marco De Bruyn, et al.
The Lancet. Oncology|January 5, 2016
TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trialElisabeth Quoix, Hervé Lena, Gyorgy Losonczy, et al.
JAMA Oncology|January 13, 2018
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung CancerLaura Mezquita, Edouard Auclin, Roberto Ferrara, et al.
Journal of Cell Science|June 15, 2022
Patient-derived organoids identify an apico-basolateral polarity switch associated with survival in colorectal cancerCharlotte Canet-Jourdan, Diane-Laure Pagès, Clémence Nguyen-Vigouroux, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 20, 2019
Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint InhibitorsLizza E L Hendriks, Clemence Henon, Edouard Auclin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2021
Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 BlockadeStéphane Terry, Cécile Dalban, Nathalie Rioux-Leclercq, et al.
The Journal of Clinical Investigation|December 28, 2018
PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancerRoman M Chabanon, Gareth Muirhead, Dragomir B Krastev, et al.
Oncoimmunology|December 8, 2018
TNFR2/BIRC3-TRAF1 signaling pathway as a novel NK cell immune checkpoint in cancerAlexandre Ivagnès, Meriem Messaoudene, Gautier Stoll, et al.
Journal for Immunotherapy of Cancer|June 24, 2021
Metabolic features of cancer cells impact immunosurveillanceAdrien Joseph, Pan Juncheng, Michele Mondini, et al.
Pageof 16

Showing results (121-130 of 152) with videos related to

Sort By:
Pageof 16
JCO Precision Oncology|September 11, 2020
Real-World Utility of an Amplicon-Based Next-Generation Sequencing Liquid Biopsy for Broad Molecular Profiling in Patients With Advanced Non-Small-Cell Lung CancerJordi Remon, Ludovic Lacroix, Cecile Jovelet, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 30, 2018
Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiativeAurélie Auguste, Catherine Genestie, Marco De Bruyn, et al.
The Lancet. Oncology|January 5, 2016
TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trialElisabeth Quoix, Hervé Lena, Gyorgy Losonczy, et al.
JAMA Oncology|January 13, 2018
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung CancerLaura Mezquita, Edouard Auclin, Roberto Ferrara, et al.
Journal of Cell Science|June 15, 2022
Patient-derived organoids identify an apico-basolateral polarity switch associated with survival in colorectal cancerCharlotte Canet-Jourdan, Diane-Laure Pagès, Clémence Nguyen-Vigouroux, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 20, 2019
Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint InhibitorsLizza E L Hendriks, Clemence Henon, Edouard Auclin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2021
Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 BlockadeStéphane Terry, Cécile Dalban, Nathalie Rioux-Leclercq, et al.
The Journal of Clinical Investigation|December 28, 2018
PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancerRoman M Chabanon, Gareth Muirhead, Dragomir B Krastev, et al.
Oncoimmunology|December 8, 2018
TNFR2/BIRC3-TRAF1 signaling pathway as a novel NK cell immune checkpoint in cancerAlexandre Ivagnès, Meriem Messaoudene, Gautier Stoll, et al.
Journal for Immunotherapy of Cancer|June 24, 2021
Metabolic features of cancer cells impact immunosurveillanceAdrien Joseph, Pan Juncheng, Michele Mondini, et al.
Pageof 16